Revelation Biosciences, Inc.

NasdaqCM:REVB Stock Report

Market Cap: US$3.6m

Revelation Biosciences Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

James Rolke

Chief executive officer

US$649.3k

Total compensation

CEO salary percentage73.2%
CEO tenure4yrs
CEO ownership0.05%
Management average tenure4yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Revelation Biosciences surges 46% on licensing deal with Vanderbilt University

Oct 06

Revelation Biosciences GAAP EPS of -$0.12

Aug 15

Revelation Biosciences stock slides 47% on pricing $5M securities offering

Jul 26

Revelation Biosciences: Therapeutics And Diagnostics For Respiratory Viral Infections

Mar 28

CEO Compensation Analysis

How has James Rolke's remuneration changed compared to Revelation Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$649kUS$475k

-US$120k

Sep 30 2023n/an/a

US$875k

Jun 30 2023n/an/a

US$2m

Mar 31 2023n/an/a

US$2m

Dec 31 2022US$480kUS$400k

-US$11m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$618kUS$400k

-US$12m

Sep 30 2021n/an/a

-US$11m

Dec 31 2020US$273kUS$167k

-US$4m

Compensation vs Market: James's total compensation ($USD649.25K) is about average for companies of similar size in the US market ($USD661.15K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


CEO

James Rolke (54 yo)

4yrs

Tenure

US$649,250

Compensation

Mr. James M. Rolke serves as Chief Executive Officer and Director at Revelation Biosciences, Inc. since May 2020. Mr. Rolke has many years of experience in the biotechnology industry, spanning all areas an...


Leadership Team

NamePositionTenureCompensationOwnership
James Rolke
CEO & Director4yrsUS$649.25k0.046%
$ 1.7k
Chester Zygmont
CFO & Corporate Secretary4yrsUS$479.14k0.040%
$ 1.5k
Sandra Vedrick
Vice President of Human Resources & Investor Relations4.3yrsno datano data
Carol Odle
Senior Director of Clinical Projectsno datano datano data

4.0yrs

Average Tenure

Experienced Management: REVB's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
James Rolke
CEO & Director4yrsUS$649.25k0.046%
$ 1.7k
George Tidmarsh
Independent Chairman4yrsUS$49.34k0.086%
$ 3.1k
Lakhmir Chawla
Independent Directorless than a yearUS$15.00kno data
Jess Roper
Independent Director3.6yrsUS$79.34k0.0025%
$ 90.2
Jennifer Carver
Independent Director4yrsUS$109.34k0.0065%
$ 233.2
Julia Bohannon
Member of Scientific Advisory Board1.2yrsno datano data
Antonio Hernandez
Member of Scientific Advisory Board1.2yrsno datano data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Board: REVB's board of directors are considered experienced (3.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.